Appointment of Joint Corporate Broker
In brief · summary, not quotable
No summary for this filing – the full text is below.
Full announcement
Select text to share a quote on X · sign in to keep highlights & notes in your OXB notes
Oxford, UK - 15 February 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led cell and gene therapy CDMO, today announces the appointment of RBC Capital Markets as the Company's joint corporate broker, to work alongside J.P.Morgan Cazenove, with immediate effect.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.